The CHTN mission is to provide prospectively procured biospecimens to scientific investigators with the ability to modify procurement and specimen processing procedures to suit the individual protocol of each investigator. Basic demographic information and clinicopathologic data abstracted from pathology reports are provided to investigators. More detailed clinical annotation may be obtained by arrangement.
Most tissue specimens procured by the CHTN are distributed to investigators as fresh/viable aliquots or snap-frozen. Quality control (QC) for all tissue samples consists of histologic analysis of a paired formalin-fixed paraffin-embedded (FFPE) tissue segment that is examined by a board-certified anatomic pathologist ensuring the delivery of correct tissue type and the elimination of highly necrotic specimens (Fig. A).
For tumor specimens, tumor cellularity, percent stroma and percent necrosis are also recorded (Fig. B). The histologic QC procedures created by the... Read more
June 23, 2017 at 10AM EDTSponsored by the NIH Data Science Special Interest GroupNational Library of Medicine
The NIH Data Science Special Interest Group is proud to host the webinar Global Perspective on Biobanking and Access to Samples on Friday June 23, 2017 at 10 am EDT. Biobanking leaders from around the world will discuss the challenges and obstacles in sharing and accessing samples and their associated data. The discussion will also address samples that are scarce and how to overcome challenges associated with obtaining these samples. The online audience will be able to send questions directly to the panelists through the GoToWebinar interface. We hope the webinar will facilitate further discussion on these issues and generate new ideas for possible solution and collaboration.Panelists include:
Jonathan Pevsner, Professor, at the Dept. of Neurology, Kennedy Krieger Institute, Dept. of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine. Presentation:... Read more
The revised American Joint Committee on Cancer (AJCC) Cancer Staging Manual1 was recently released with a new staging system for all cancer cases diagnosed on or after January 1, 2018. The 8th edition of the Cancer Staging Manual represents an important step in refining the anatomic staging system traditionally based on primary tumor extent and nodal and distant metastasis (TNM) by including non-anatomic factors in prognostic groupings. While the TNM components remain purely anatomic, many of the staging algorithms in the 8th edition of the Cancer Staging Manual incorporate molecular and serologic factors into new staging systems designed to reflect the current state of medical knowledge and the natural history and prognosis of cancers. Some of the noteworthy advances in this edition include:
The Cooperative Human Tissue Network (CHTN) and the International Society for Biological and Environmental Repositories (ISBER) are closely linked. For example, Dee McGarvey, CHTN Eastern Division Coordinator, prepared two ISBER webinars on Best Practices, one on Safety and another on Specimen Collection and Processing.
Members of the CHTN divisions are participating in several ISBER activities at this week’s 2017 Annual Meeting of ISBER in Toronto, Canada (May 9-12). CHTN members attending and participating in this week’s activities include:Dee McGarvey, CHTN Eastern Division Coordinator Zack Von Menchhofen, CHTN Eastern Division IT Representative Craig Rumpel, CHTN Mid-Atlantic Division Coordinator Dr. Leona W. Ayers, CHTN Midwestern Division Principal Investigator Randy Mandt, CHTN Midwestern Division Coordinator Dr. William E. Grizzle, CHTN Southern Division Principal Investigator Kathy C. Sexton, CHTN Southern Division Coordinator
CHTN members are also involved... Read more
In addition to procuring and distributing biospecimens following the usual CHTN procedures, the CHTN Pediatric Division (pCHTN) also has a unique and longstanding relationship with the Children’s Oncology Group (COG). This relationship allows the pCHTN to distribute COG banked biospecimens once all clinical trial-specific correlative science studies are completed. Although the pCHTN is not a bank, this partnership gives CHTN investigators access to the precious clinically-annotated biospecimens maintained by COG. In this setting, applications for these biospecimens are handled by the pCHTN, but the availability of the biospecimens is determined by the COG’s specific Disease Committees following detailed evaluation of the scientific value of each application.
One of the latest and far-reaching COG initiatives is Project:EveryChild. The COG states the following:
“There are approximately 14,000 new cases of childhood cancer each year in the United States. The most common... Read more